Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.19)
# 2,869
Out of 5,055 analysts
35
Total ratings
51.61%
Success rate
-5.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Outperform | $775 → $910 | $929.61 | -2.11% | 5 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $1.79 | +682.12% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $234.00 | -5.13% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $72.21 | +23.25% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.05 | +143.90% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $11.34 | +102.82% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.39 | +151.05% | 2 | Dec 20, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $17.54 | +869.21% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.81 | +315.80% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $208.25 | -1.08% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.45 | +797.96% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.50 | +300.00% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $77.35 | -22.43% | 1 | Oct 5, 2022 |
argenx SE
Oct 31, 2025
Maintains: Outperform
Price Target: $775 → $910
Current: $929.61
Upside: -2.11%
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $1.79
Upside: +682.12%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $234.00
Upside: -5.13%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $72.21
Upside: +23.25%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.05
Upside: +143.90%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $11.34
Upside: +102.82%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.39
Upside: +151.05%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $17.54
Upside: +869.21%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.81
Upside: +315.80%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $208.25
Upside: -1.08%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $2.45
Upside: +797.96%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.50
Upside: +300.00%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $77.35
Upside: -22.43%